Miana Leonardo Augusto, Azeka Estela, Canêo Luiz Fernando, Turquetto Aída Luisa, Tanamati Carla, Penha Juliano Gomes, Cauduro Alexandre, Jatene Marcelo Biscegli
InCor, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Rev Bras Cir Cardiovasc. 2014 Jul-Sep;29(3):322-9. doi: 10.5935/1678-9741.20140106.
Cardiac transplantation remains the gold standard for end-stage cardiomyopathies and congenital heart defects in pediatric patients.
This study aims to report on 20 years of experience since the first case and evaluate our results.
We conducted a retrospective analysis of the database and outpatient follow-up. Between October 1992 and April 2012, 109 patients underwent 114 transplants. 51.8% of them being female. The age of patients ranged from 12 days to 21 years with a mean of 8.8±5.7 years and a median of 5.2 years. The underlying diagnosis was dilated cardiomyopathy in 61.5%, congenital heart disease in 26.6% and restrictive cardiomyopathy in 11.9%. All patients above 17 years old had congenital heart disease.
Survival rate at 30 days, 1, 5, 10, 15, and 20 years were 90.4%, 81.3%, 70.9%, 60.5%, 44.4% and 26.7%, respectively. Mean cold ischemic time was 187.9 minutes and it did not correlate with mortality (P>0.05). Infectious complications and rejection episodes were the most common complications (P<0.0001), occurring, respectively, in 66% and 57.4% of the survivors after 10 years. There was no incidence of graft vascular disease and lymphoproliferative disease at year one, but they affected, respectively, 7.4% and 11% of patients within 10 years.
Twenty-year pediatric heart transplant results at our institution were quite satisfactory and complication rates were acceptable.
心脏移植仍然是小儿终末期心肌病和先天性心脏缺陷的金标准。
本研究旨在报告自首例病例以来20年的经验并评估我们的结果。
我们对数据库和门诊随访进行了回顾性分析。1992年10月至2012年4月期间,109例患者接受了114次移植手术。其中51.8%为女性。患者年龄从12天至21岁不等,平均年龄为8.8±5.7岁,中位数为5.2岁。潜在诊断为扩张型心肌病的占61.5%,先天性心脏病的占26.6%,限制型心肌病的占11.9%。所有17岁以上的患者均患有先天性心脏病。
30天、1年、5年、10年、15年和20年的生存率分别为90.4%、81.3%、70.9%、60.5%、44.4%和26.7%。平均冷缺血时间为187.9分钟,与死亡率无关(P>0.05)。感染并发症和排斥反应是最常见的并发症(P<0.0001),10年后分别发生在66%和57.4%的幸存者中。术后1年无移植血管疾病和淋巴增生性疾病发生,但10年内分别有7.4%和11%的患者受其影响。
我们机构20年小儿心脏移植结果相当令人满意,并发症发生率可以接受。